Scinai Immunotherapeutics Ltd. (NasdaqCM: SCNI)
Health Care · Biotechnology · IL
$2.89
-10.25% today · -79.1% 1Y
Scinai Immunotherapeutics Ltd. (NasdaqCM: SCNI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.28M and employs 45 people.
Over the last twelve months the share price has lost 79.1%, trading between 2.15 and 17.20.
Tweenvest scores Scinai Immunotherapeutics Ltd. across four factors: quality 32/100, value 49/100. Its strongest factor is value.
SCNI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.28M
- Revenue (TTM)
- $1.21M
- P/E
- —
- EPS
- -11.34
- Dividend yield
- —
- Beta (5Y)
- 2.09
- 52-week high
- $17.20
- 52-week low
- $2.15
- Avg volume (3M)
- —
- Shares outstanding
- 395.98K
- Employees
- 45
- Next earnings
- —
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
- ISIN
- US09073Q4029
- Founded
- 2003
- Listed since
- May 11, 2015
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.42 | -1.27% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.10 | -0.48% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.70 | -0.05% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.79 | -0.55% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $822.15 | -1.37% |
| argenx SEENXTBR: ARGX | $64.17B | €889.60 | +1.18% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.44 | -5.91% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.